对37例服用云芝糖肽的食管癌患者,于服药前后,用细胞毒方法测定患者外周血中的T淋巴细胞亚群,T_3、T_4、T_8细胞数,T_4/T_8比值;以双抗体夹心法测定血清中的SIL-2R,以天然细胞毒测定—LDH释放法检测NK细胞杀伤活性,服用云芝糖肽后,T_3、T_4、T_8淋巴细胞亚群及NK细胞杀伤活性较服药前显著增高(P<0.05),血清中SIL-2R显著下降(P<0.05)。说明云芝糖肽为一较好的免疫调节剂,可作为食管癌治疗的辅助药物。 For 37 patients with esophageal cancer who took Yunzhi glycopeptide, before and after taking the drug, the T lymphocyte subsets in the peripheral blood of the patient were measured by cytotoxicity method, T_3, T_4, T_8 cell number, T_4/T_8 ratio; sandwiched with double antibody The serum SIL-2R was measured by natural cytotoxicity assay-LDH release assay to detect the killing activity of NK cells. After taking PSK, the killing activity of T3, T4, T8 lymphocyte subsets and NK cells was significantly higher than before administration. (P<0.05), serum SIL-2R decreased significantly (P<0.05). Description Yunzhi glycopeptide is a good immune regulator, can be used as an adjuvant drug for the treatment of esophageal cancer.